Search Results
You are looking at 101 - 110 of 503 items for
- Abstract: Aging x
- Abstract: Late effects of cancer treatment x
Search for other papers by Agnieszka Adamska in
Google Scholar
PubMed
Search for other papers by Paulina Tomczuk-Bobik in
Google Scholar
PubMed
Search for other papers by Anna Beata Popławska-Kita in
Google Scholar
PubMed
Search for other papers by Katarzyna Siewko in
Google Scholar
PubMed
Search for other papers by Angelika Buczyńska in
Google Scholar
PubMed
Search for other papers by Piotr Szumowski in
Google Scholar
PubMed
Search for other papers by Łukasz Żukowski in
Google Scholar
PubMed
Search for other papers by Janusz Myśliwiec in
Google Scholar
PubMed
Search for other papers by Monika Zbucka-Krętowska in
Google Scholar
PubMed
Search for other papers by Marcin Adamski in
Google Scholar
PubMed
Clinical Research Centre, Medical University of Bialystok, Białystok, Poland
Search for other papers by Adam Jacek Krętowski in
Google Scholar
PubMed
Treatment with radioactive iodine (RAI) in women with differentiated thyroid cancer is associated with decreased serum concentrations of anti-Müllerian hormone (AMH); however, other markers have not been investigated. Therefore, this study aimed to evaluate the effect of RAI treatment on antral follicle count (AFC) and the serum concentration of inhibin B, follicle-stimulating hormone (FSH), and AMH in women with papillary thyroid cancer (PTC) treated with RAI. We examined 25 women at a median age of 33 years treated with a single dose of RAI. We divided the participants into women over (n = 11) and under 35 years of age (n = 14). Serum concentrations of inhibin B, FSH, AMH, and AFC were assessed at baseline and 1 year after RAI treatment. We found decreased AFC (P = 0.03), serum levels of AMH (P < 0.01), inhibin B (P = 0.03), but not FSH (P = 0.23), 1 year after RAI treatment in comparison to baseline in the whole group. When we compared serum levels of AMH in younger vs older women separately, we observed a significant reduction of this hormone’s serum level after RAI treatment in both groups (P < 0.01; P = 0.04, respectively). We concluded that RAI treatment significantly impacts the functional ovarian reserve in premenopausal women with PTC.
Search for other papers by Adriano N Cury in
Google Scholar
PubMed
Search for other papers by Verônica T Meira in
Google Scholar
PubMed
Pediatric Endocrinology Unit, Endocrinology and Metabolism, Nuclear Medicine Laboratory, Pediatrics Department, Irmandade da Santa Casa de Misericórdia de São Paulo, 01221-020 São Paulo, Brazil
Search for other papers by Osmar Monte in
Google Scholar
PubMed
Search for other papers by Marília Marone in
Google Scholar
PubMed
Search for other papers by Nilza M Scalissi in
Google Scholar
PubMed
Search for other papers by Cristiane Kochi in
Google Scholar
PubMed
Search for other papers by Luís E P Calliari in
Google Scholar
PubMed
Search for other papers by Carlos A Longui in
Google Scholar
PubMed
Background/aims
Treatments for Graves' disease (GD) in children and adolescents include oral antithyroid drugs (ATDs), near total thyroidectomy, and radioactive iodine (RAI). ATDs remain the preferred choice in this age group, but because persistent remission occurs in 30% of cases, RAI is becoming a common option for definitive therapy.
Methods
We performed a review of 65 medical records of GD patients under age 19 years who were followed between 1985 and 2005.
Results
The prevalence of GD was higher in females (3:1) and during puberty (for both genders). If no remission was detected during ATD treatment, RAI was indicated when the following criteria were present: non-compliance, relapse, or side effects that were related to ATDs, large goiter, and long-term use of ATDs. The majority of patients developed hypothyroidism within 6 months after RAI. A progressive higher dose regimen was implemented in the last 10 years of the study period. A second RAI dose was necessary in eight cases. During the follow-up period, three pregnancies occurred. One patient with a thyroid nodule and benign cytology was detected.
Conclusions
RAI therapy is effective and safe in the treatment of GD in children and adolescents.
Search for other papers by Kusum Lata in
Google Scholar
PubMed
Search for other papers by Pinaki Dutta in
Google Scholar
PubMed
Search for other papers by Subbiah Sridhar in
Google Scholar
PubMed
Search for other papers by Minakshi Rohilla in
Google Scholar
PubMed
Search for other papers by Anand Srinivasan in
Google Scholar
PubMed
Search for other papers by G R V Prashad in
Google Scholar
PubMed
Search for other papers by Viral N Shah in
Google Scholar
PubMed
Search for other papers by Anil Bhansali in
Google Scholar
PubMed
Objectives
Thyroid antibody positivity during pregnancy has been associated with adverse outcomes including miscarriage and preterm delivery. The aim of the study is to evaluate the obstetric outcome in pregnant women with recurrent miscarriage and their response to levothyroxine (l-T4) therapy.
Study design and methods
All pregnant and non-pregnant women between 21 and 35 years of age with a history of two or more consecutive miscarriages were included in the study. A third group comprising 100 pregnant women without a history of miscarriage were taken as healthy controls. Thyroid autoimmunity, prevalence of subclinical hypothyroidism and maternal and foetal complications were analysed in all the groups with appropriate statistical methods.
Results
The mean age of the patients included in the study was 27.0±3.1 years. Of 100 pregnant patients with previous recurrent miscarriage, thyroid autoimmunity (thyroid peroxidase antibody (TPOAb+) >34 U/ml) was found in 31% of the cases. The incidence of subclinical hypothyroidism was higher in TPOAb+ group than in TPOAb− group (52 vs 16%; P=0.0002). There was no difference in the prevalence of miscarriage or obstetric outcomes between recurrent miscarriage and healthy pregnant women group irrespective of TPO status.
Conclusions
The prevalence of thyroid autoimmunity was higher in pregnant women with a history of recurrent abortion compared with healthy pregnant control population. Following l-T4 treatment, there was no difference in prevalence of miscarriage between hypothyroid and euthyroid individuals in TPOAb+ women.
Search for other papers by Lawrence D Hayes in
Google Scholar
PubMed
Search for other papers by Peter Herbert in
Google Scholar
PubMed
Search for other papers by Nicholas F Sculthorpe in
Google Scholar
PubMed
Search for other papers by Fergal M Grace in
Google Scholar
PubMed
As the impact of high-intensity interval training (HIIT) on systemic hormones in aging men is unstudied to date, we investigated whether total testosterone (TT), sex hormone-binding globulin (SHBG), free testosterone (free-T) and cortisol (all in serum) were altered following HIIT in a cohort of 22 lifelong sedentary (62 ± 2 years) older men. As HIIT requires preconditioning exercise in sedentary cohorts, participants were tested at three phases, each separated by six-week training; baseline (phase A), following conditioning exercise (phase B) and post-HIIT (phase C). Each measurement phase used identical methods. TT was significantly increased following HIIT (~17%; P < 0.001) with most increase occurring during preconditioning (~10%; P = 0.007). Free-T was unaffected by conditioning exercise (P = 0.102) but was significantly higher following HIIT compared to baseline (~4.5%; P = 0.023). Cortisol remained unchanged from A to C (P = 0.138). The present data indicate a combination of preconditioning, and HIIT increases TT and SHBG in sedentary older males, with the HIIT stimulus accounting for a small but statistically significant increase in free-T. Further study is required to determine the biological importance of small improvements in free-T in aging men.
Search for other papers by E N Dudinskaya in
Google Scholar
PubMed
Search for other papers by O N Tkacheva in
Google Scholar
PubMed
Search for other papers by M V Shestakova in
Google Scholar
PubMed
Search for other papers by N V Brailova in
Google Scholar
PubMed
Search for other papers by I D Strazhesko in
Google Scholar
PubMed
Search for other papers by D U Akasheva in
Google Scholar
PubMed
Search for other papers by O Y Isaykina in
Google Scholar
PubMed
Search for other papers by N V Sharashkina in
Google Scholar
PubMed
Search for other papers by D A Kashtanova in
Google Scholar
PubMed
Search for other papers by S A Boytsov in
Google Scholar
PubMed
It is known that glucose disturbances contribute to micro- and macrovascular complications and vascular aging. Telomere length is considered to be a cellular aging biomarker. It is important to determine the telomere length role in vascular structural and functional changes in patients with diabetes mellitus. We conducted a cross-sectional observational study in a high-risk population from Moscow, Russia. The study included 50 patients with diabetes and without clinical cardiovascular disease and 49 control group participants. Glucose metabolism assessment tests, measuring intima–media complex thickness and determining the presence of atherosclerotic plaques, pulse wave velocity measurement, and telomere length measurement were administered to all participants. Vascular changes were more dramatic in patients with diabetes than in the control group, and the telomeres were shorter in patients with diabetes. Significant differences were found in the vascular wall condition among diabetes patients, and there were no substantial differences in the arterial structure between patients with ‘long’ telomeres; however, there were statistically significant differences in the vascular wall condition between patients with ‘short’ telomeres. Vascular ageing signs were more prominent in patients with diabetes. However, despite diabetes, vascular changes in patients with long telomeres were very modest and were similar to the vascular walls in healthy individuals. Thus, long lymphocyte telomeres may have a protective effect on the vascular wall and may prevent vascular wall deterioration caused by glucose metabolism disorders.
Search for other papers by S U Jayasinghe in
Google Scholar
PubMed
Search for other papers by S J Torres in
Google Scholar
PubMed
Search for other papers by C A Nowson in
Google Scholar
PubMed
Search for other papers by A J Tilbrook in
Google Scholar
PubMed
Search for other papers by A I Turner in
Google Scholar
PubMed
We tested the hypothesis that overweight/obese men aged 50–70 years will have a greater salivary cortisol, salivary alpha amylase and heart rate (HR) responses to psychological stress compared with age matched lean men. Lean (BMI=20–25 kg/m2; n=19) and overweight/obese (BMI=27–35 kg/m2; n=17) men (50–70 years) were subjected to a well-characterised psychological stress (Trier Social Stress Test, TSST) at 1500 h. Concentrations of cortisol and alpha amylase were measured in saliva samples collected every 7–15 min from 1400 to 1700 h. HR was recorded using electrocardiogram. Body weight, BMI, percentage body fat, resting systolic and diastolic blood pressure and mean arterial pressure were significantly higher (P<0.05) in overweight/obese men compared with lean men. Both groups responded to the TSST with a substantial elevation in salivary cortisol (372%), salivary alpha amylase (123%) and HR (22%). These responses did not differ significantly between the groups (time×treatment interaction for salivary cortisol, salivary alpha amylase and HR; P=0.187, P=0.288, P=0.550, respectively). There were no significant differences between the groups for pretreatment values, peak height, difference between pretreatment values and peak height (reactivity) or area under the curve for salivary cortisol, salivary alpha amylase or HR (P>0.05 for all). The results showed that, for men with a moderate level of overweight/obesity who were otherwise healthy, the response of salivary cortisol, salivary alpha amylase and HR to acute psychological stress was not impaired.
Structural and Functional Biology Program, Universidade Federal de São Paulo, São Paulo, Brazil
Search for other papers by Erika Urbano Lima in
Google Scholar
PubMed
Structural and Functional Biology Program, Universidade Federal de São Paulo, São Paulo, Brazil
Search for other papers by Ileana G S Rubio in
Google Scholar
PubMed
Post-graduate Program in Interactive Processes of Organs and Systems, Health & Science Institute, Federal University of Bahia, Salvador, Brazil
Search for other papers by Joaquim Custodio Da Silva in
Google Scholar
PubMed
Search for other papers by Ana Luiza Galrão in
Google Scholar
PubMed
Post-graduate Program in Interactive Processes of Organs and Systems, Health & Science Institute, Federal University of Bahia, Salvador, Brazil
Search for other papers by Danielle Pêssoa in
Google Scholar
PubMed
Search for other papers by Taise Cerqueira Oliveira in
Google Scholar
PubMed
Post-graduate Program in Interactive Processes of Organs and Systems, Health & Science Institute, Federal University of Bahia, Salvador, Brazil
Search for other papers by Fabiane Carrijo in
Google Scholar
PubMed
Search for other papers by Igor Silva Campos in
Google Scholar
PubMed
Department of Anatomic Pathology & Legal Medicine, Bahia Federal Medical School, Federal University of Bahia, Salvador, Brazil
Search for other papers by Luciano Fonseca Espinheira in
Google Scholar
PubMed
Search for other papers by Luiz Jose Sampaio in
Google Scholar
PubMed
Search for other papers by Claudio Rogerio Lima in
Google Scholar
PubMed
Division of Genetics, Department of Morphology and Genetics, Genetic Basis of Thyroid Tumors Laboratory, Paulista School of Medicine, Universidade Federal de São Paulo, São Paulo, Brazil
Search for other papers by Janete Maria Cerutti in
Google Scholar
PubMed
Post-graduate Program in Interactive Processes of Organs and Systems, Health & Science Institute, Federal University of Bahia, Salvador, Brazil
Search for other papers by Helton Estrela Ramos in
Google Scholar
PubMed
Background
The inactivation of the tumor-suppressor homeodomain-only protein X (HOPX) usually involves promoter methylation in several cancer types. This study aimed to investigate the HOPX-β mRNA expression and promoter methylation and their clinical relevance in differentiated thyroid cancer (DTC).
Patients and methods
Clinicopathological data and paraffin-embedded thyroid tumor tissues from 21 patients with DTC and 6 with benign tumors (T) and their non-tumor parenchyma (NT) were investigated. Tumor cell lines (FTC238, FTC236 and WRO) were treated with demethylating agent. HOPX-β mRNA expression was assessed by qRT-PCR and methylation status by Q-MSP. Thyroid cancer data from Cancer Genome Atlas (TCGA) was also collected.
Results
HOPX-β mRNA re-expression in two cell lines treated with demethylating agent was observed concomitantly with reduced promoter methylation. Reduced mRNA expression in T group compared to their NT was observed, and reduced protein expression in T compared to NT was observed in three cases. Low mRNA expression with high methylation status was detected in 6/14 DTC samples. High methylation status was associated with older age at diagnosis, recurrent or progressive disease and with the presence of new neoplasm event post initial therapy while hyper-methylation correlated with worse overall survival, worse disease-free status and older age.
Conclusion
A moderate coupling of downregulation of HOPX-β mRNA expression in DTC followed by high HOPX-β promoter methylation was observed however; high HOPX promoter methylation status was associated with the worse prognosis of DTC patients.
Search for other papers by Nadia Sawicka-Gutaj in
Google Scholar
PubMed
Search for other papers by Ariadna Zybek-Kocik in
Google Scholar
PubMed
Search for other papers by Michał Kloska in
Google Scholar
PubMed
Search for other papers by Paulina Ziółkowska in
Google Scholar
PubMed
Search for other papers by Agata Czarnywojtek in
Google Scholar
PubMed
Search for other papers by Jerzy Sowiński in
Google Scholar
PubMed
Search for other papers by Dorota Mańkowska-Wierzbicka in
Google Scholar
PubMed
Search for other papers by Marek Ruchała in
Google Scholar
PubMed
Dysregulation of thyroid function has known impact on body metabolism, however, data regarding metabolic outcome after restoration of thyroid function is limited. Therefore, the aim of the study was to investigate the effect of restoration of euthyroidism on serum visfatin, and its associations with insulin resistance and body composition. This is an observational study with consecutive enrollment. Forty-nine hyperthyroid (median age of 34 years) and 44 hypothyroid women (median age of 46 years) completed the study. Laboratory parameters and body composition analysis were assessed before and after the therapy. In the hyperthyroid group, visfatin concentrations increased (P < 0.0001), while glucose concentrations decreased (P < 0.0001). Total body mass and fat mass in the trunk and limbs significantly increased during the treatment. In the hypothyroid group, significant weight loss resulted from decrease of fat and muscle masses in trunk and limbs. Visfatin serum concentrations positively correlated with total fat mass (r = 0.19, P = 0.01) and insulin concentrations (r = 0.17, P = 0.018). In conclusion, restoration of thyroid function is not associated with beneficial changes in body composition, especially among hyperthyroid females.
Search for other papers by Nandini Shankara Narayana in
Google Scholar
PubMed
Search for other papers by Lam P Ly in
Google Scholar
PubMed
Search for other papers by Veena Jayadev in
Google Scholar
PubMed
Search for other papers by Carolyn Fennell in
Google Scholar
PubMed
Search for other papers by Sasha Savkovic in
Google Scholar
PubMed
Search for other papers by Ann J Conway in
Google Scholar
PubMed
Search for other papers by David J Handelsman in
Google Scholar
PubMed
Objective
To define the optimized inter-injection interval of injectable testosterone undecanoate (TU) treatment for hypogonadal and transmen based on individual dose titration in routine clinical practice.
Design and methods
A prolective observational study of consecutive TU injections in men undergoing testosterone replacement therapy for pathological hypogonadism or masculinization of female-to-male transgender (transmen) subject to individual dosing titration to achieve a stable replacement regimen.
Results
From 2006 to 2019, 6899 injections were given to 325 consecutive patients. After excluding the 6-week loading dose, 6300 injections were given to 297 patients who had at least three and a median of 14 injections. The optimal injection interval (mean of last three injection intervals) had a median of 12.0 weeks (interquartile range 10.4–12.7 weeks). The interval was significantly influenced by age and body size (body surface area, BSA) but not by diagnosis or trough serum LH, FSH, and SHBG. Longer (≥14 weeks; 68/297, 23%), but not shorter (≤10 weeks; 22/297, 7.4%), intervals were weakly correlated with age but not diagnosis or other covariables. Low blood hemoglobin increased with trough serum testosterone to reach plateau once testosterone was about 10 nmol/L or higher.
Conclusion
Optimal intervals between TU injection after individual titration resulted in the approved 12-week interval in 70% of patients with only minor influence for clinical application of BSA and not of trough serum LH, FSH, and SHBG. Individually optimized inter-injection interval did not differ between men with primary or secondary hypogonadism or transmen.
Search for other papers by B Fabre in
Google Scholar
PubMed
Search for other papers by G Maccallini in
Google Scholar
PubMed
Search for other papers by A Oneto in
Google Scholar
PubMed
Search for other papers by D Gonzalez in
Google Scholar
PubMed
Search for other papers by V Hirschler in
Google Scholar
PubMed
Search for other papers by C Aranda in
Google Scholar
PubMed
Search for other papers by G Berg in
Google Scholar
PubMed
Background
Saliva is a useful sample as a source of hormones for the diagnosis of different diseases, particularly in pediatric patients and aged individuals, because saliva offers a noninvasive and stress-free alternative to serum collection. The aim of this study was to validate a salivary insulin method and to check its clinical application in pediatric patients.
Methods
Saliva samples were collected from 130 boys and 147 girls aged 6–14 years. Salivary and serum insulin levels were measured with the chemiluminescent automated method Access (Beckman Coulter, Brea, CA, USA). Serum blood glucose levels were measured with the glucose oxidase method in an autoanalyzer.
Results
The precision profile of the method was determined for six aliquots of different concentrations from pools of saliva, and the coefficients of variation (CV) were 2.4% for 1 μUI/ml, 4% for 0.5, 8.9% for 0.25, 19% for 0.12, 28% for 0.06, and 38% for 0.03 μUI/ml, being the functional sensibility (concentration corresponding to a 20% CV) 0.12 μUI/ml. Insulin recovery was 100.13%. Salivary insulin levels diminished 29.8% in samples stored during 7 days at 2–8 °C. Differences in insulin values were not observed when samples were stored at −20 °C during 7 days. The methods used to measure salivary and serum insulin correlated significantly (r=0.92, P<0.001). However, at levels of serum insulin >20 μUI/ml, this correlation declined (r=0.57, P=0.083).
Conclusion
The proposed method for salivary insulin measurement showed convenient analytical characteristics.
